BCM
BOLT icon

Bridgeway Capital Management’s Bolt Biotherapeutics BOLT Stock Holding History

Bridgeway Capital Management’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,010
Closed -$32.2K – 1184
2024
Q4 		$32.2K Hold
3,010
– – ﹤0.01% 1173
2024
Q3 		$39K Sell
3,010
-1,250
-29% -$17.2K ﹤0.01% 1226
2024
Q2 		$63.9K Sell
4,260
-1,300
-23% -$25.6K ﹤0.01% 1203
2024
Q1 		$156K Hold
5,560
– – ﹤0.01% 1146
2023
Q4 		$125K Hold
5,560
– – ﹤0.01% 1210
2023
Q3 		$116K Buy
5,560
+500
+10% +$12.2K ﹤0.01% 1199
2023
Q2 		$130K Buy
5,060
+1,300
+35% +$41.3K ﹤0.01% 1214
2023
Q1 		$105K Sell
3,760
-5,620
-60% -$164K ﹤0.01% 1231
2022
Q4 		$244K Buy
9,380
+3,720
+66% +$102K 0.01% 1035
2022
Q3 		$168K Buy
5,660
+2,385
+73% +$98.7K ﹤0.01% 1168
2022
Q2 		$134K Sell
3,275
-2,500
-43% -$97.1K ﹤0.01% 1171
2022
Q1 		$316K Buy
+5,775
New +$389K 0.01% 1060

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's BOLT Position: Q1 2025 in Review

Bridgeway Capital Management sold out of Bolt Biotherapeutics (BOLT) in Q1 2025, closing a stake of 3,010 shares — an estimated $32.2K sold.

Bridgeway Capital Management first reported a position in BOLT in Q1 2022 and held it in 12 quarters. The position peaked at $316K in Q1 2022. 29 funds tracked by Wall St. Rank hold BOLT as of Q1 2025.

  • Bridgeway Capital Management reported no remaining Bolt Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 3,010 Bolt Biotherapeutics shares in Q1 2025, an estimated $32.2K.
  • Bridgeway Capital Management first reported a position in Bolt Biotherapeutics in Q1 2022 and held it in 12 quarters.
  • Bridgeway Capital Management's Bolt Biotherapeutics position peaked at $316K in Q1 2022.
  • 29 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2025.

Based on Bridgeway Capital Management's 13F filing for Q1 2025, filed 15 May 2025.